BioSpace News Archive

Real Time Medical Systems (Real Time), the leading interventional analytics solution in healthcare, joins the THA Center for Innovative Solutions (TCIS) as its newest Strategic Partner.

Solano Hematology Oncology and Deep Lens today announced a strategic collaboration designed to more effectively identify, screen and match patients to precision-based clinical oncology trials using VIPER™, Deep Lens’ artificial intelligence-based screening and enrollment platform

Partnership between Shields Health Solutions and Sentara Healthcare brings patients more support services, increased number of specialty drugs and expanded insurance coverage

In tandem with its research and development partner, Lobo Genetics Inc. (“Lobo”), HaluGen has successfully developed a turn-key operation to build, order, ship, process and deliver its Psychedelics Genetic Test.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma

- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 3, 2021 to report its fourth quarter and full-year 2020 financial results and discuss recent business highlights.

- Centene Corporation (NYSE: CNC) announced today its Hawaii subsidiary ‘Ohana Health Plan was selected to continue administering services through the Community Care Services (CCS) program in partnership with the Hawaii Department of Human Services’ Med-QUEST Division.

electroCore, Inc., a commercial-stage bioelectronic medicine company and the Hospital Clínico Universitario de Valencia in Spain, announced the completion of patient enrollment in SAVIOR-1, or “Prospective, Randomized, Controlled Study to Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19.” This study was supported in part by electroCore.

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March: Cowen’s 41 st Annual Health Care Conference

- H.C. Wainwright: Global Life Sciences Conference - March 9 th – 10 th - Oppenheimer 31 st Annual Healthcare Conference - March 16 th – 17 th